Ro 08-2750

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Ro 08-2750  纯度: 95.01%

Ro 08-2750 是一种非肽、可逆的 NGF 抑制剂，能直接结合 NGF，IC50 值为 ~ 1 µM。Ro 08-2750 能抑制 NGF 结合 p75NTR 的优于 TRKA。Ro 08-2750 是选择性的 MSI RNA 结合抑制剂，其作用的 IC50 值为 2.7 μM。

Ro 08-2750

Ro 08-2750 Chemical Structure

CAS No. : 37854-59-4

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥4608 询价
1 mg ￥1550 In-stock
5 mg ￥4650 询价
10 mg   询价  
50 mg   询价  

* Please select Quantity before adding items.

Ro 08-2750 相关产品

•相关化合物库:

  • Covalent Screening Library Plus
  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Anti-Cancer Compound Library
  • Covalent Screening Library
  • Anti-Blood Cancer Compound Library
  • Targeted Diversity Library

生物活性

Ro 08-2750 is a non-peptide and reversible nerve growth factor (NGF) inhibitor which binds to NGF, and with an IC50 of ~ 1 µM. Ro 08-2750 inhibits NGF binding to p75NTR selectively over TRKA[1]. Ro 08-2750 is a selective MSI RNA-binding activity inhibitor, with an IC50 of 2.7 μM[3].

IC50 & Target

IC50: ~1 µM (NGF)[1], 2.7 μM (MSI RNA-binding)[3]
体外研究
(In Vitro)

Ro 08-2750 binds to the NGF dimer thereby probably inducing a change in its conformation such that NGF cannot bind to p75NTR anymore[2].
Ro 08-2750 (10 nM) completely rescues cells from undergoing NGF-induced SK-N-MC 103 cells death[2].
Ro 08-2750 (5-10 μM; 8 hours) increases differentiation and apoptosis in myeloid leukemia cells[3].
Ro 08-2750 inhibits survival of human AML lines and patient cells[3].
Ro 08-2750 inhibits MSI2 RNA-binding and alters MSI2 gene signature[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis[3]

Cell Line: MLL-AF9 + BM cells
Concentration: 5 μM, 10 μM
Incubation Time: 8 hours
Result: Increased apoptosis.

体内研究
(In Vivo)

Ro 08-2750 (13.75 mg/kg; i.p.) inhibits leukemogenesis in a myeloid leukemia model in vivo[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 wild type mice (10-12-weeks-old), MLL-AF9 murine leukemia model[3]
Dosage: 13.75 mg/kg
Administration: Intraperitoneal injection, at days 1, 4, 7, 10, and 13 (one day on, two days off drug)
Result: Inhibited c-MYC levels and reduced disease burden.

分子量

270.24

Formula

C13H10N4O3
CAS 号

37854-59-4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 4 mg/mL (14.80 mM; ultrasonic and warming and heat to 80°C)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.7004 mL 18.5021 mL 37.0041 mL
5 mM 0.7401 mL 3.7004 mL 7.4008 mL
10 mM 0.3700 mL 1.8502 mL 3.7004 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Arkin MR, et al. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov. 2004 Apr;3(4):301-17.

    [2]. Niederhauser O, et al. NGF ligand alters NGF signaling via p75(NTR) and trkA. J Neurosci Res. 2000 Aug 1;61(3):263-72.

    [3]. Minuesa G, et al. Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia. Nat Commun. 2019 Jun 19;10(1):2691.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务